These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11338934)

  • 1. Technology evaluation: C242-DM1, ImmunoGen Inc.
    Smith S
    Curr Opin Mol Ther; 2001 Apr; 3(2):198-203. PubMed ID: 11338934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.
    Tassone P; Gozzini A; Goldmacher V; Shammas MA; Whiteman KR; Carrasco DR; Li C; Allam CK; Venuta S; Anderson KC; Munshi NC
    Cancer Res; 2004 Jul; 64(13):4629-36. PubMed ID: 15231675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.
    Liu C; Tadayoni BM; Bourret LA; Mattocks KM; Derr SM; Widdison WC; Kedersha NL; Ariniello PD; Goldmacher VS; Lambert JM; Blättler WA; Chari RV
    Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8618-23. PubMed ID: 8710920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technology evaluation: cantuzumab mertansine, ImmunoGen.
    Smith SV
    Curr Opin Mol Ther; 2004 Dec; 6(6):666-74. PubMed ID: 15663331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
    Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
    Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semisynthetic maytansine analogues for the targeted treatment of cancer.
    Widdison WC; Wilhelm SD; Cavanagh EE; Whiteman KR; Leece BA; Kovtun Y; Goldmacher VS; Xie H; Steeves RM; Lutz RJ; Zhao R; Wang L; Blättler WA; Chari RV
    J Med Chem; 2006 Jul; 49(14):4392-408. PubMed ID: 16821799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
    Al-Katib AM; Aboukameel A; Mohammad R; Bissery MC; Zuany-Amorim C
    Clin Cancer Res; 2009 Jun; 15(12):4038-45. PubMed ID: 19509168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
    Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
    Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy.
    Lu SX; Takach EJ; Solomon M; Zhu Q; Law SJ; Hsieh FY
    J Pharm Sci; 2005 Apr; 94(4):788-97. PubMed ID: 15729708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.
    Kovtun YV; Audette CA; Ye Y; Xie H; Ruberti MF; Phinney SJ; Leece BA; Chittenden T; Blättler WA; Goldmacher VS
    Cancer Res; 2006 Mar; 66(6):3214-21. PubMed ID: 16540673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revival of a potent therapeutic maytansinoid agent using a strategy that combines covalent drug conjugation with sequential nanoparticle assembly.
    Xie K; Song S; Zhou L; Wan J; Qiao Y; Wang M; Xie H; Zhou L; Zheng S; Wang H
    Int J Pharm; 2019 Feb; 556():159-171. PubMed ID: 30553007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
    Chari RV; Martell BA; Gross JL; Cook SB; Shah SA; Blättler WA; McKenzie SJ; Goldmacher VS
    Cancer Res; 1992 Jan; 52(1):127-31. PubMed ID: 1727373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Technology evaluation: SGN-15, Seattle Genetics Inc.
    Smith S
    Curr Opin Mol Ther; 2001 Jun; 3(3):295-302. PubMed ID: 11497354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts.
    Ostermann E; Garin-Chesa P; Heider KH; Kalat M; Lamche H; Puri C; Kerjaschki D; Rettig WJ; Adolf GR
    Clin Cancer Res; 2008 Jul; 14(14):4584-92. PubMed ID: 18628473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.
    Erickson HK; Park PU; Widdison WC; Kovtun YV; Garrett LM; Hoffman K; Lutz RJ; Goldmacher VS; Blättler WA
    Cancer Res; 2006 Apr; 66(8):4426-33. PubMed ID: 16618769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage.
    Kellogg BA; Garrett L; Kovtun Y; Lai KC; Leece B; Miller M; Payne G; Steeves R; Whiteman KR; Widdison W; Xie H; Singh R; Chari RV; Lambert JM; Lutz RJ
    Bioconjug Chem; 2011 Apr; 22(4):717-27. PubMed ID: 21425776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
    Safavy A; Bonner JA; Waksal HW; Buchsbaum DJ; Gillespie GY; Khazaeli MB; Arani R; Chen DT; Carpenter M; Raisch KP
    Bioconjug Chem; 2003; 14(2):302-10. PubMed ID: 12643740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technology evaluation: huN901-DM1, ImmunoGen.
    Smith SV
    Curr Opin Mol Ther; 2005 Aug; 7(4):394-401. PubMed ID: 16121706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy.
    Feng L; Yao HP; Wang W; Zhou YQ; Zhou J; Zhang R; Wang MH
    Clin Cancer Res; 2014 Dec; 20(23):6045-58. PubMed ID: 25294907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.